TherapeuticsMD (NASDAQ:TXMD) Issues Quarterly Earnings Results, Beats Estimates By $6.07 EPS

TherapeuticsMD (NASDAQ:TXMD) released its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.07, reports. TherapeuticsMD had a return on equity of 0.27% and a net margin of 10.80%.The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $19.77 million.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $1.99 on Tuesday. TherapeuticsMD has a fifty-two week low of $0.84 and a fifty-two week high of $2.95. The firm has a market cap of $23.02 million, a price-to-earnings ratio of -199.00 and a beta of 0.51. The firm has a 50 day moving average price of $2.30 and a 200-day moving average price of $1.77.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC boosted its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,273 shares of the company’s stock after purchasing an additional 19,073 shares during the period. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent reporting period. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.